Zevra Therapeutics, Inc. ZVRA AFS Securities
AFS Securities at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s afs securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s AFS securities?
- Zevra Therapeutics, Inc. (ZVRA) reported AFS securities of $36.1M in Q1 2026.
- How has Zevra Therapeutics, Inc.'s AFS securities changed year-over-year?
- Zevra Therapeutics, Inc.'s AFS securities increased by 492.7% year-over-year, from $6.09M to $36.1M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s AFS securities?
- Over 4 years (2021 to 2025), Zevra Therapeutics, Inc.'s AFS securities has grown at a 33.8% compound annual growth rate (CAGR), from $14.93M to $47.88M.
- What does AFS securities mean?
- Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.